// App-Quantinova.ai

DOP001 : Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study

Researchers

Presenter

  • U Kopylov

Principal Investigators

  • L Biedermann

  • S Sebastian

  • D Pugliese

  • E Sonnenberg

  • P R Steinhagen

  • N Arebi

  • Y Ron

  • T Kucharzik

  • X Roblin

  • B Ungar

  • A Bar-Gil Shitrit

  • S Ardizzone

  • P Molander

  • M Coletta

  • L Peyrin-Biroulet

  • P Bossuyt

  • I Avni-Biron

  • E I Tsoukal

  • M Allocca

  • K Katsanos

  • T Raine

  • T Sipponen

  • G Fiorino

  • S Ben-Horin

  • R Eliakim

  • A Armuzzi

  • B Siegmund

  • D C Baumgart

  • N Kamperidis

  • N Maharshak

  • C Maaser

  • G Mantzaris

  • H Yanai

  • D Christodoulou

  • I Dotan

  • M Ferrante

Medical Centers

  • Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel

  • Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium

  • University Hospital Zurich, Division of Gastroenterology & Hepatology, Zurich, Switzerland

  • Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom

  • Complesso Integrato Columbus, Fondazione Policlinico Gemelli Universita' Cattolica, Internal Medicine and Gastroenterology, Rome, Italy

  • Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology and Medicine I, Berlin, Germany

  • LNWH ST MARKS HOSPITAL, Harrow, UK

  • Tel Aviv Medical Centre, IBD Centre, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel

  • University Teaching Hospital Lüneburg, Department of Internal Medicine and Gastroenterology, Lüneburg, Germany

  • CHU de Saint-Etienne, Gastroenterology, Saint-Etiennne, France

  • Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel

  • ASST Fatebenefratelli Sacco, Milan, Italy

  • Helsinki University Central Hospital, Department of Gastroenterology, Department of Medicine, Helsinki, Finl

  • Department of Pathophysiology and Transplantation, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy, Gatroenterology, Milan, Italy

  • Nancy University Hospital, Universite de Lorraine, Gastroenterology and Hepatology, Vandoeuvre-les-Nancy, France

  • Imelda GI Clinical Research Centre, Department of Gastroenterology, Bonheiden, Belgium

  • Sheba Medical Center, Department of Gastroenterology and Liver Diseases, Ramat Gan, Israel

  • Evangelismos Hospital, Gastroenterology Department, Athens, Greece

  • Humanitas Gradenigo, Gastroenterology, Turin, Italy

  • University of Ioannina, Gastroenterology, Ioannina, Greece

  • Addenbrookes hospital, Cambridge University hospitals NHS Foundation trust, Department of Paediatric Gastroenterology, Cambridge, United Kingdom

  • Helsinki University Central Hospital - Meilahti Hospital, Department of Gastroenterology, Helsinki, Finl

  • Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy

Locations

  • Israel

  • Belgium

  • Switzerland

  • United Kingdom

  • Italy

  • Germany

  • France

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved